Innate Pharma (IPHYF) News Today $2.90 0.00 (0.00%) (As of 12/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Mesoblast (NASDAQ:MESO) versus Innate Pharma (OTCMKTS:IPHYF) Financial AnalysisDecember 19 at 3:57 AM | americanbankingnews.comPositive Outlook for Innate Pharma: Buy Rating Supported by Promising Lacutamab Phase 2 Results and Strong Financial PositionDecember 9, 2024 | markets.businessinsider.comInnate Pharma SA’s Innovations Spotlighted at ASH 2024December 3, 2024 | msn.comEvercore ISI Sticks to Its Buy Rating for Innate Pharma (IPHA)November 14, 2024 | markets.businessinsider.comInnate Pharma’s New CEO and Promising FDA FeedbackNovember 14, 2024 | markets.businessinsider.comInnate Pharma S.A. (OTCMKTS:IPHYF) Short Interest Up 22.4% in SeptemberInnate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the target of a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 6,000 shares, a growth of 22.4% from the September 15th total of 4,900 shares. Based on an average daily volume of 600 shares, the days-to-cover ratio is currently 10.0 days.October 15, 2024 | marketbeat.comInnate Pharma Names Jonathan Dickinson CEO, Executive Board ChairmanOctober 14, 2024 | marketwatch.comInnate Pharma (NASDAQ:IPHA) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comInnate Pharma Rings the Closing BellOctober 4, 2024 | nasdaq.comFDA grants IND clearance for Innate Pharma’s solid tumour trialSeptember 23, 2024 | finance.yahoo.comKepler Capital Sticks to Its Hold Rating for Innate Pharma SA (IPHYF)September 11, 2024 | markets.businessinsider.comInnate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024September 9, 2024 | finance.yahoo.comInnate Pharma S.A. (OTCMKTS:IPHYF) Short Interest Down 8.8% in AugustInnate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the target of a large decline in short interest in the month of August. As of August 15th, there was short interest totalling 6,200 shares, a decline of 8.8% from the July 31st total of 6,800 shares. Based on an average trading volume of 500 shares, the days-to-cover ratio is presently 12.4 days.September 1, 2024 | marketbeat.comInnate Pharma S.A. (OTCMKTS:IPHYF) Short Interest Up 23.6% in JulyInnate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 6,800 shares, an increase of 23.6% from the July 15th total of 5,500 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.August 17, 2024 | marketbeat.comInnate Pharma S.A. (OTCMKTS:IPHYF) Sees Large Growth in Short InterestInnate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) saw a significant growth in short interest in June. As of June 15th, there was short interest totalling 7,900 shares, a growth of 43.6% from the May 31st total of 5,500 shares. Based on an average trading volume of 1,100 shares, the short-interest ratio is presently 7.2 days.July 1, 2024 | marketbeat.comShort Interest in Innate Pharma S.A. (OTCMKTS:IPHYF) Declines By 6.8%Innate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the recipient of a significant decline in short interest in May. As of May 15th, there was short interest totalling 5,500 shares, a decline of 6.8% from the April 30th total of 5,900 shares. Based on an average trading volume of 2,200 shares, the short-interest ratio is currently 2.5 days.June 3, 2024 | marketbeat.comInnate Pharma Announces Its Participation in Upcoming Investor ConferencesMay 28, 2024 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Innate Pharma Amidst Promising Platforms and Strategic Growth PotentialApril 16, 2024 | markets.businessinsider.comInnate Pharma (OTCMKTS:IPHYF) Stock Price Up 2.7%Innate Pharma (OTCMKTS:IPHYF) Stock Price Up 2.7%April 3, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Innate Pharma SA (OtherIPHYF), Medios AG (OtherMEDOF) and Tecan Group AG (OtherTCHBF)March 23, 2024 | markets.businessinsider.comInnate Pharma Stock (OTC:IPHYF), Insider Trading ActivityFebruary 26, 2024 | benzinga.comInnate Pharma SA (IPHYF) Receives a Hold from Kepler CapitalFebruary 4, 2024 | markets.businessinsider.comInnate Pharma: Worth A Deeper LookJanuary 11, 2024 | seekingalpha.comAnalysts Conflicted on These Healthcare Names: Innate Pharma SA (OtherIPHYF), Amgen (AMGN) and Regeneron (REGN)January 6, 2024 | markets.businessinsider.comInnate Pharma Up 4% After FDA Lifts Partial Clinical Hold on LacutamabJanuary 4, 2024 | marketwatch.comShort Interest in Innate Pharma S.A. (OTCMKTS:IPHYF) Expands By 650.0%Innate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 4,500 shares, a growth of 650.0% from the November 30th total of 600 shares. Based on an average daily volume of 200 shares, the days-to-cover ratio is currently 22.5 days.December 28, 2023 | marketbeat.comInnate Pharma and Sanofi to license natural killer cell engagerDecember 19, 2023 | msn.comBuy Rating for Innate Pharma Backed by Promising Lacutamab Clinical Results and Regulatory ProspectsDecember 14, 2023 | markets.businessinsider.comInnate Pharma to Host Virtual KOL Event on LacutamabNovember 27, 2023 | finance.yahoo.comInnate Pharma Announces Conference Call for Third Quarter 2023 Business UpdateNovember 7, 2023 | finance.yahoo.comInnate Pharma Announces Its Participation to Upcoming Investor ConferencesOctober 27, 2023 | finance.yahoo.comInnate Pharma Announces Abstracts Selected for ESMO Congress 2023October 16, 2023 | finance.yahoo.comInnate Pharma Shares Fall Premarket on FDA Partial Study HoldOctober 5, 2023 | marketwatch.comRegulatory Hurdle For Innate Pharma's Blood Cancer StudiesOctober 5, 2023 | msn.comInnate Pharma Says FDA Places Partial Clinical Hold On Lacutamab IND; Stock Down 10%October 5, 2023 | markets.businessinsider.comInnate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023September 22, 2023 | finance.yahoo.comFirst Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple MyelomaJuly 11, 2023 | finance.yahoo.comNumber of Shares and Voting Rights of Innate Pharma as of July 1, 2023July 7, 2023 | finance.yahoo.comKepler Capital Reaffirms Their Hold Rating on Innate Pharma SA (IPHYF)June 18, 2023 | markets.businessinsider.comADRs End Higher, Innate Pharma and Medigus Trade ActivelyJune 8, 2023 | marketwatch.comInnate Pharma Shares Rise 8% After Cancer Treatment Gets Fast Track DesignationJune 8, 2023 | marketwatch.comInnate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AMLMay 26, 2023 | finance.yahoo.comInnate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 CongressMay 15, 2023 | finance.yahoo.comH.C. Wainwright Reaffirms Their Buy Rating on Innate Pharma (IPHA)May 11, 2023 | markets.businessinsider.comInnate Pharma Reports First Quarter 2023 Financial Results and Business UpdateMay 10, 2023 | finance.yahoo.comInnate Pharma Establishes a New At-The-Market ("ATM") Program on NasdaqApril 26, 2023 | finance.yahoo.comSVB Securities Keeps Their Buy Rating on Innate Pharma (IPHA)April 12, 2023 | markets.businessinsider.comInnate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-FApril 6, 2023 | finance.yahoo.comInnate Pharma SA (IPHYF) Gets a Hold from Kepler CapitalApril 4, 2023 | markets.businessinsider.com Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter. Email Address Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED. Click here to see the details because I believe a lot of people will get rich. IPHYF Media Mentions By Week IPHYF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPHYF News Sentiment▼0.000.60▲Average Medical News Sentiment IPHYF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPHYF Articles This Week▼10▲IPHYF Articles Average Week Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Poseida Therapeutics News Immatics News Replimune Group News LENZ Therapeutics News Relay Therapeutics News Anavex Life Sciences News Cullinan Therapeutics News Autolus Therapeutics News CARGO Therapeutics News Tectonic Therapeutic News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:IPHYF) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IPHYF Stock Alerts